188 related articles for article (PubMed ID: 36272970)
21. Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.
Kraus RJ; Yu X; Cordes BA; Sathiamoorthi S; Iempridee T; Nawandar DM; Ma S; Romero-Masters JC; McChesney KG; Lin Z; Makielski KR; Lee DL; Lambert PF; Johannsen EC; Kenney SC; Mertz JE
PLoS Pathog; 2017 Jun; 13(6):e1006404. PubMed ID: 28617871
[TBL] [Abstract][Full Text] [Related]
22. The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.
Yetming KD; Lupey-Green LN; Biryukov S; Hughes DJ; Marendy EM; Miranda JL; Sample JT
J Virol; 2020 Aug; 94(17):. PubMed ID: 32581094
[TBL] [Abstract][Full Text] [Related]
23. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
[TBL] [Abstract][Full Text] [Related]
24. The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells.
Westhoff Smith D; Chakravorty A; Hayes M; Hammerschmidt W; Sugden B
mBio; 2021 Dec; 12(6):e0224321. PubMed ID: 34781735
[TBL] [Abstract][Full Text] [Related]
25. Identification of Host Biomarkers of Epstein-Barr Virus Latency IIb and Latency III.
Messinger JE; Dai J; Stanland LJ; Price AM; Luftig MA
mBio; 2019 Jul; 10(4):. PubMed ID: 31266868
[TBL] [Abstract][Full Text] [Related]
26. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
Wood CD; Carvell T; Gunnell A; Ojeniyi OO; Osborne C; West MJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021904
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus co-opts TFIIH component XPB to specifically activate essential viral lytic promoters.
Verma D; Church TM; Swaminathan S
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):13044-13055. PubMed ID: 32434920
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
Longnecker R
Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
[TBL] [Abstract][Full Text] [Related]
29. Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation.
Price AM; Luftig MA
Adv Virus Res; 2014; 88():279-313. PubMed ID: 24373315
[TBL] [Abstract][Full Text] [Related]
30. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection.
Shannon-Lowe C; Rowe M
PLoS Pathog; 2011 May; 7(5):e1001338. PubMed ID: 21573183
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection.
Mrozek-Gorska P; Buschle A; Pich D; Schwarzmayr T; Fechtner R; Scialdone A; Hammerschmidt W
Proc Natl Acad Sci U S A; 2019 Aug; 116(32):16046-16055. PubMed ID: 31341086
[TBL] [Abstract][Full Text] [Related]
33. Suppression of JAK-STAT Signaling by Epstein-Barr Virus Tegument Protein BGLF2 through Recruitment of SHP1 Phosphatase and Promotion of STAT2 Degradation.
Jangra S; Bharti A; Lui WY; Chaudhary V; Botelho MG; Yuen KS; Jin DY
J Virol; 2021 Sep; 95(20):e0102721. PubMed ID: 34319780
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus subverts mevalonate and fatty acid pathways to promote infected B-cell proliferation and survival.
Wang LW; Wang Z; Ersing I; Nobre L; Guo R; Jiang S; Trudeau S; Zhao B; Weekes MP; Gewurz BE
PLoS Pathog; 2019 Sep; 15(9):e1008030. PubMed ID: 31518366
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus infection of Langerhans cell precursors as a mechanism of oral epithelial entry, persistence, and reactivation.
Walling DM; Ray AJ; Nichols JE; Flaitz CM; Nichols CM
J Virol; 2007 Jul; 81(13):7249-68. PubMed ID: 17376908
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes.
Farina A; Peruzzi G; Lacconi V; Lenna S; Quarta S; Rosato E; Vestri AR; York M; Dreyfus DH; Faggioni A; Morrone S; Trojanowska M; Farina GA
Arthritis Res Ther; 2017 Feb; 19(1):39. PubMed ID: 28245863
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr Virus (EBV) Latent Protein EBNA3A Directly Targets and Silences the
Bazot Q; Paschos K; Allday MJ
J Virol; 2018 Apr; 92(7):. PubMed ID: 29367247
[TBL] [Abstract][Full Text] [Related]
38. The biological properties of different Epstein-Barr virus strains explain their association with various types of cancers.
Tsai MH; Lin X; Shumilov A; Bernhardt K; Feederle R; Poirey R; Kopp-Schneider A; Pereira B; Almeida R; Delecluse HJ
Oncotarget; 2017 Feb; 8(6):10238-10254. PubMed ID: 28052012
[TBL] [Abstract][Full Text] [Related]
39. Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming.
McClellan MJ; Wood CD; Ojeniyi O; Cooper TJ; Kanhere A; Arvey A; Webb HM; Palermo RD; Harth-Hertle ML; Kempkes B; Jenner RG; West MJ
PLoS Pathog; 2013 Sep; 9(9):e1003636. PubMed ID: 24068937
[TBL] [Abstract][Full Text] [Related]
40. Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus.
Martin HJ; Lee JM; Walls D; Hayward SD
J Virol; 2007 Sep; 81(18):9748-58. PubMed ID: 17609264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
